3D Printed Drugs Market Size & Share, by Technology (Inkjet Printing, Zipdose Technology, Stereolithography); Application (Orthopedic, Neurology); End-user (Hospitals, Clinics, Research Laboratories) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 421
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2033

3D Printed Drugs Market size is poised to reach USD 530 Million by the end of 2033, growing at a CAGR of 7% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of 3D printed drugs was over USD 200 Million. The growth of the market can be attributed primarily to the rising 3D printing of pharmaceuticals. For instance, 3D printing of pharmaceuticals have increased year on year Valued at USD 174 million in 2020 and anticipated to grow to USD 28 million by 2025. In 2020, the 3D printing of pharmaceuticals accounted for USD 174 million and is expected to reach USD 28 million by 2025. There is an opportunity to capitalize on the benefits and overcome the challenges associated with 3D printing of pharmaceuticals.

Powder-liquid three-dimensional (3DP) printing technologies are used to develop 3D printed drugs. By using an aqueous fluid, different layers of powder can be bonded and multiple products can be produced. Three-dimensional powder-liquid drugs or pills are comparatively more soluble than two-dimensional drugs or pills. Furthermore, 3D printed drugs are able to dissolve insoluble compounds such as silver chloride very easily. 3D printed high dose drugs can also be dissolved within seconds, making them more acceptable. As well as this, 3D-printed drugs are comparatively reliable pills when taken at the right dosage. Moreover, rising number of chronic diseases, rising adoption of technological advancements, advantages of 3D printed drugs over general drugs such as low cost and better solubility along with, growing demand for self-medication. For instance, approximately 90% of surgical and medical wards have policies allowing patients to self-administrate.  

Get more information on this report: Request Free Sample PDF

3D Printed Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence Of Diseases Among Children Such As Pneumonia -For instance, approximately 2,000 children are killed by pneumonia every day, which is more than any other infectious disease. More than 200,000 of them are newborns.Taking medication could therefore become much easier for children who are resistant to taking the medication they need owing to 3D printed drugs. The first benefit of these tablets is that they may be able to choose the shape, color and design of the tablet, as well as its taste. The increasing number of diseases among children are contributing to the increased adoption of these drugs, which is anticipated to drive global drugs market over the forecast period.
  • Increase In Research And Development Expenditures- As per World Bank data, global research and development expenditures contributed 2.63% to GDP in 2020. Compared to 2018, this represents a considerable increase from 2.2%.
  • A Global Increase In Healthcare Spending- Approximately 19.7% of the nation's GDP was accounted for by healthcare expenditures in 2020, according to a report released by the Centers for Medicare & Medicaid Services. 
  • Growing Incidence of Non Communicable Diseases- Worldwide, noncommunicable diseases (NCDs) cause 41 million deaths each year, accounting for 74% of all deaths. It is estimated that 17 million people die of a NCD before they reach 70 years of age every year; 86% of these premature deaths happen in countries with low and middle incomes.
  • Global Increase In Geriatric Population- The World Bank recently reported that 747,238,580 people over 60 years of age lived worldwide at the end of 2021. Future projections predict a rise in the number.


  • Unapproval Of 3D Printed Drugs In Many Countries
  • Drug Shortages Due To COVID-19 
  • Inadequacies In Government Regulations Regarding 3D Printing

3D Printed Drugs Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

USD 200 Million

Forecast Year Market Size (2033)

USD 530 Million

Get more information on this report: Request Free Sample PDF

3D Printed Drugs Segmentation

Technology (Inkjet Printing, Zipdose Technology, Stereolithography)

The global 3D printed drugs market is segmented and analyzed for demand and supply by technology into inkjet printing, zipdose technology, and stereolithography. Among these segments, the zipdose technology segment is anticipated to capture the largest market size in the global 3D printed drugs market owing to the rise in the number of people suffering from dysphagia. It was observed that the prevalence of dysphagia in hospitalized patients ranges from 15% to 17%. Approximately 31% to 59% of nursing home residents suffer from dysphagia symptoms. In addition to being easy to use, this makes swallowing the drugs easier and proves to be effective for patients with dysphagia. Moreover, the growing demand for quickly dispersible drugs among geriatric and pediatric patients is expected to augment segment growth over the forecast period.

Our in-depth analysis of the global drugs market includes the following segments:

          By Technology

  • Inkjet Printing
  • Zipdose Technology
  • Stereolithography

          By Application

  • Orthopedic
  • Neurology


           By End User

  • Hospitals
  • Clinics
  • Research Laboratories

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

3D Printed Drugs Industry - Regional Synopsis

Regionally, the global 3D printed drugs market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033 owing to the growing incidence of chronic diseases and increasing health awareness among people. For instance, 44% of the population suffers from at least one chronic illness, which amounts to over 132 million Americans. Over 1.6 million Americans die every year from chronic diseases in the United States. Furthermore, the well-developed domestic healthcare infrastructure, extensive research and development, and increasing technological advancements in the North America region are anticipated to drive the regional market growth over the forecast period.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the 3D Printed Drugs Landscape

    • Extend Biosciences
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bioduro
    • Affinity Therapeutics
    • Osmotica Pharmaceuticals
    • Acrux
    • Thiomatrix
    • Ico Therapeutics Inc.
    • Formac Pharmaceuticals
    • BiopharmX
    • Pacira Pharmaceuticals Inc.


In The News

  • Pacira Pharmaceuticals Inc and sevredent sourcing solutions partnered to provide exparel to patients undergoing oral and maxillofacial treatments

  • Affinity Therapeutics raised USD 175 million for the development of engineered T cell therapies for cancers that are difficult to treat. The launch is one of the biggest biotech launches of the year.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 421
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising geriatric population, growing prevalence of chronic diseases, along with advantages of 3D printed drugs over general drugs such as low cost and better solubility are the major factors driving the growth of the 3D printed drugs market.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2033.

Unapproval of 3D printed drugs in many countries and drug shortages due to COVID-19 are the challenges affecting the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Extend Biosciences, Bioduro, Affinity Therapeutics, Osmotica Pharmaceuticals, Acrux, Thiomatrix, Ico Therapeutics Inc., Formac Pharmaceuticals, BiopharmX and Pacira Pharmaceuticals Inc.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by technology, application, end user and, by region.

The zipdose segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
3D Printed Drugs Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying